• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

871026-44-7 (TAK-285)



TAK-285 TAK-285
Name TAK-285
Formula C26H25ClF3N5O3
MW 547.96
CAS No. 871026-44-7
Smiles ClC(C=C(NC1=NC=NC2=C1N(CCNC(CC(C)(C)O)=O)C=C2)C=C3)=C3OC4=CC=CC(C(F)(F)F)=C4
Synonyms TAK285; TAK 285; N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide
InChI InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34)


TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.

Background Information

TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. IC50 value: 17/23 nM (HER2/1) [1] Target: HER1/2 in vitro: MEK1, MEK5, c-Met, Aurora B, Lck, CSK, and Lyn B with IC50 of 1.1 μM, 5.7 μM, 4.2 μM, 1.7 μM, 2.4 μM, 4.7 μM, and 5.2 μM, respectively, and displays no activity against other kinases with IC50 of >10 μM. TAK-285 shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI50 of 17 nM [1]. Compared with SYR127063 a potent inhibitor of HER2, TAK-285 displays similar in vitro potency against HER2 and EGFR. Compared with the full cytoplasmic domains of the wild-type proteins, the mutations and shortened boundaries used for structure determination of HER2-KD and EGFR-KD do not significantly change the inhibitory activity (IC50) of TAK-285. TAK-285 binds to the inactive conformation of EGFR, and shows a similar binding mode with lapatinib in the active site [2]. in vivo: The oral bioavailability of TAK-285 is 97.7% in rats and 72.2% in mice at a dose of 50 mg/kg. Oral administration of TAK-285 at 100 mg/kg twice daily for 14 days displays significant antitumor efficacy in the HER2-overexpressing BT-474 tumor xenograft mouse model with tumor/control (T/C) ratio of 29%, without affecting body weight. Similar to the BT-474 model, TAK-285 exhibits dose-dependent tumor growth inhibition of 4-1ST (HER2-overexpressing human gastric cancer tumor) xenografts in mice, with T/C of 44% and 11% at doses of 50 mg/kg and 100 mg/kg, twice daily, respectively, without significant body weight loss in mice [1]. After oral administration of TAK-285, a significant amount of TAK-285 is present in the brain of rats in pharmacologically active, unbound form (approximately 20% of its free plasma level), indicating that TAK-285 has a potential in the therapy of CNS malignancies/metastases [3]. ......by MedChemexpress Co., Ltd.
TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is currently being developed by Takeda. TAK-285 was found to be well tolerate in Phase I trials. Absorption of TAK-285 was rapid after oral dosing, and plasma exposure at steady-state increased in a dose-proportional fashion for doses ranging from 50 to 300?mg b.i.d. A partial response was observed for one patient with parotid cancer who received 300?mg b.i.d. The toxicity profile and PK properties of oral TAK-285 warrant further evaluation. (source: Br J Cancer. 2012 Feb 14;106(4):666-72.) Shelf life: >2 years if stored properly Drug formulation: ......by MedKoo Biosciences, Inc.
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1. ......by Selleck Chemicals LLC
TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1. ......by Target Molecule Corp.

Protocol(Only for Reference)

Cell Experiment

Cell lines BT-474
Conditions Dissolved in DMSO, final concentrations ~10 μM; 5 days
Method The cells are treated continuously with various concentrations of TAK-285 for 5 days. The live cell numbers are counted with a particle analyzer.
Source Selleck Chemicals LLC

Animal Experiment

Animal Models Female BALB/c nu/nu mice bearing BT-474 or 4-1ST xenografts, and female nude rats (F344/N Jcl-rnu) bearing 4-1ST xenografts
Dosage ~100 mg/kg/day
Formulation Suspended in 0.5% (w/v) methylcellulose solution
Administration Orally twice daily
Source Selleck Chemicals LLC

Physical and Chemical Properties

Appearance:White to off-white solid EBNumber:EB000022588

Storage condition


DMSO 110 mg/ml by MedChemexpress Co., Ltd.
(25°C) * In vitro DMSO 110 mg/mL (200.74 mM); Ethanol54 mg/mL (98.54 mM); Water<1 mg/mL (<1 mM) by Selleck Chemicals LLC

Mechanism and Indication

Signaling Pathways JAK/STAT Signaling Protein Tyrosine Kinase/RTK
Target EGFR
Research Area Cancer

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
TAK-285 - Discontinued
TAK-285 - Phase 1

Safety Data of TAK-285


Spectral Information


Suppliers List

Company Price and Availability Country/Region
Aladdin 5mg/RMB3333();10mg/RMB5803();50mg/RMB20621() China
Apexbio Technology LLC 5mg/USD189(In stock) USA
CHEMSCENE, LLC 5mg/USD220(In stock);10mg/USD400(In stock);50mg/USD1250(In stock) USA
KareBay Biochem 5mg/USD230() USA
MedChemexpress Co., Ltd. 5mg/USD220(In stock);10mg/USD400(In stock);50mg/USD1250(In stock) USA
MedKoo Biosciences, Inc. USA
Santa Cruz Biotechnology, Inc. 5mg/USD405() USA
Selleck Chemicals LLC 5mg/USD270(In stock);10mg/USD470(In stock);50mg/USD1670(In stock);100mg/USD2470(In stock) USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD220(In stock);10mg/USD400(In stock);50mg/USD1250(In stock) China
Target Molecule Corp. 5mg/USD172();10mg/USD285();50mg/USD960() USA

Related Products

Other Forms of 871026-44-7

Name CAS No Formula MW

Recommended Compounds in EGFR

Name CAS No Formula MW
Ginsenoside Rh2 78214-33-2 C36H62O8 622.87
Mutated EGFR-IN-1 1421372-66-8 C25H31N7O 445.56
AZD-9291 (mesylate) 1421373-66-1 C29H37N7O5S 595.71
Mutant EGFR inhibitor 1421373-62-7 C27H30ClN7O2 520.03
AZD-9291 1421373-65-0 C28H33N7O2 499.61
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
WHI-P180 211555-08-7 C16H15N3O3 297.31
Gefitinib (hydrochloride) 184475-55-6 C22H25Cl2FN4O3 483.36
Erlotinib (mesylate) 248594-19-6 C23H27N3O7S 489.54
BGB-102 807640-87-5 C22H25BrN4O2 457.36
Poziotinib 1092364-38-9 C23H21Cl2FN4O3 491.34
CO-1686 (hydrobromide) 1446700-26-0 C27H29BrF3N7O3 636.46
CO-1686 1374640-70-6 C27H28F3N7O3 555.55
CNX-2006 1375465-09-0 C26H27F4N7O2 545.53
PD 168393 194423-15-9 C17H13BrN4O 369.22
AG 18 118409-57-7 C10H6N2O2 186.17
Afatinib (dimaleate) 850140-73-7 C32H33ClFN5O11 718.08
Chrysophanic acid 481-74-3 C15H10O4 254.24
AG-1478 153436-53-4 C16H14ClN3O2 315.75
Mubritinib 366017-09-6 C25H23F3N4O2 468.47

Recommended Compounds in Same Indication

Name CAS No Formula MW

Route of Synthesis




More Information


Tags: buy 871026-44-7 IC50 | 871026-44-7 price | 871026-44-7 cost | 871026-44-7 solubility | 871026-44-7 purchase | 871026-44-7 manufacturer | 871026-44-7 research buy | 871026-44-7 order | 871026-44-7 MSDS | 871026-44-7 chemical structure | 871026-44-7 Storage condition | 871026-44-7 molecular weight | 871026-44-7 mw | 871026-44-7 datasheet | 871026-44-7 supplier | 871026-44-7 cell line | 871026-44-7 NMR | 871026-44-7 MS | 871026-44-7 IR | 871026-44-7 solubility | 871026-44-7 Safe information | 871026-44-7 Qc and Spectral Information | 871026-44-7 Clinical Information | 871026-44-7 Clinical Trial | 871026-44-7 Route of Synthesis | 871026-44-7 storage condition | 871026-44-7 diseases and conditions | 871026-44-7 flash point | 871026-44-7 boiling point | 871026-44-7 melting point | 871026-44-7 storage condition | 871026-44-7 brand